The last 12 months have been a bit boring for Novartis AG (NYSE:NVS) and have resulted in a lack of my coverage updates on the company. The stock has delivered a total return of around 18% since my ...

The model is designed to provide individuals more certainty about the out-of-pocket costs for these generic Part D drugs for common conditions, such as high cholesterol and high blood pressure, CMS ...

The Food and Drug Administration on Tuesday quietly approved a generic form of mifepristone, one of the two medications used in most U.S. abortions. That makes the drug, from the company Evita ...

The decision enraged opponents of abortion, who have been pressuring the Trump administration to restrict access to abortion medication. By Pam Belluck The Food and Drug Administration has approved a ...

ANDERLECHT, Belgium--(BUSINESS WIRE)--A.forall is pleased to announce the acquisition of four FDA-approved injectable generics and two late-stage pipeline assets from Provepharm's US portfolio. With ...

Medications are rarely made from start to finish in a single country; raw materials, active ingredients and final products often cross multiple borders before reaching patients in the U.S., The New ...

Forbes contributors publish independent expert analyses and insights. Sally Pipes is a scholar and think tank CEO who writes on health care. America’s generic drug market is one of our greatest health ...

Hello, and welcome to a health podocy. I'm your host, Rob Lott. I'll admit that I have a relatively simple understanding of the relationship between brand name drugs and generic drugs. Generally, I ...

Listen to more stories on the Noa app. Inflation was high, economic growth was stagnant, and food prices were soaring: It was the 1970s, and everyone needed to eat to stay alive, but no one had any ...

Implementing the Medicare $2 drug list model would have reduced out-of-pocket spending by 63% for Part D beneficiaries in 2021. The model caps cost-sharing at $2 for a 30-day supply of 101 generic ...

Generic medicines form the backbone of treatment accessibility across Europe, yet their impact extends far beyond simply being cheaper alternatives to brand-name drugs. These medications account for a ...